CRESTOR is a member of the statin class; for the treatment of dyslipidaemia. CRESTOR reduces LDL-C (‘bad’ cholesterol) and raises HDL-C (‘good’ cholesterol).
CRESTOR was initially developed by the Japanese pharmaceutical company Shionogi and in-licensed to AstraZeneca in April 1998.For Summary of Product Characteristics and Patient Information Leaflet click this link
Approval ID: 155,827.011
Date of preparation: June 2014